Loading clinical trials...
Loading clinical trials...
REduction of rIsk for Contrast-Induced Nephropathy (REICIN) Study:RESCIND-P (Prospective Observational Study for REduction of contraSt-induced Nephropathy and Cardiaovascular Events followINg carDiac Catheterization)
Conditions
Locations
12
China
Kaihong Chen
Longyan, Fujian, China
Guoliang Jia
Dongguan, Guangdong, China
Jianfeng Ye
Dongguan, Guangdong, China
Jian Qiu
Guangzhou, Guangdong, China
Jingfeng Wang
Guangzhou, Guangdong, China
Ken Wu
Guangzhou, Guangdong, China
Start Date
January 1, 2013
Primary Completion Date
February 1, 2016
Completion Date
November 1, 2018
Last Updated
August 3, 2018
NCT04982419
NCT03121053
NCT01976299
NCT01144091
NCT00312117
NCT01400295
Lead Sponsor
Guangdong Provincial People's Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions